Core Insights - Webull's CEO Anthony Denier anticipates that the B2B business will match or exceed the retail business in the coming years, marking a significant strategic shift for the company [1] Financial Performance - Webull reported Q4 revenue of $165.2 million, a 53% increase year-over-year, surpassing estimates [1] - Full-year 2025 revenue reached $571 million, up 46% from 2024 [1] - Customer assets hit an all-time high of $24.6 billion, reflecting an 81% year-over-year increase [1] - Net deposits for Q4 were $3.9 billion, a remarkable 225% increase year-over-year [1] - Reported EPS was $0.01, missing the $0.05 estimate, primarily due to a doubling of marketing and branding expenditures to $53.25 million [1] Strategic Initiatives - The partnership with Meritz Financial Group in Korea has already facilitated over $1 billion in equity trades for Korean customers, with expectations for a tenfold increase in volume by year-end [1] - The company is focusing on institutional onboarding, which is expected to yield more stable revenue streams [1] - AI tool Vega is gaining traction, with 1.2 million global users per week, and approximately 12.5% of users consulting it before executing trades [1] Market Outlook - Denier indicated that January was likely the second-best month in the company's history, suggesting a strong outlook for Q1 [1] - Market volatility is seen as beneficial for Webull, as active traders tend to concentrate on options, which have higher margins than equities [1] - Despite operational momentum, the stock is down approximately 30% year-to-date, raising questions about the market's valuation of Webull as a platform business versus a traditional brokerage [1]

Core Insights - Webull Corporation (NASDAQ:BULL) is projected to double in value over the next three years, following a strong performance in 2025 with annual revenue of $571 million, representing a 46% increase from 2024 [1][5] Financial Performance - The company reported a significant growth in customer assets, which rose 81% year-over-year to $24.6 billion, supported by total net deposits of $8.6 billion for the year [1] - Webull achieved an adjusted operating profit of $110.3 million, with an operating profit margin expanding to 19.3% [1] Product and Service Expansion - The launch of Vega, an AI-powered trading assistant, has been a key highlight, assisting 1.2 million global users weekly and answering over 10 million queries [2] - The 'Webull Premium' subscription service surpassed 100,000 subscribers, contributing 30% of the platform's total assets under management [2] - The company reintroduced crypto trading to US customers and launched prediction markets, with over 152 million contracts traded in the fourth quarter [2] International Growth - Webull continued its international expansion in 2025, reaching over 760,000 funded accounts outside the US and entering new markets such as Canada and the Netherlands [3] - The platform now has 26.8 million registered users and 5.03 million funded accounts globally, maintaining a high quarterly retention rate of approximately 97% [3]

On the cost side, Webull recorded adjusted operating expenses of $460.7 million , up 24% for the year, as the company continued investing in product and market expansion. Denier said adjusted operating profit margin improved by 14.6 percentage points to 19.3% , equating to adjusted operating profit of $110.3 million .Customer assets reached $24.6 billion , up 81% year over year, including about $1 billion in assets from the acquisition of Webull Pay. Webull also posted growth in its core trading activity, w ...

Financial Data and Key Metrics Changes - Revenue grew 45% to $235.1 million, driven primarily by the compute segment, while cost of revenue increased by 24% to $107.8 million, resulting in gross margin expansion from 47% to 54% [33] - Net loss was $248 million, with an Adjusted EBITDA loss of $135.4 million, compared to a net income of $331.4 million and Adjusted EBITDA of $555.7 million in 2024, largely due to a $220 million unrealized mark-to-market loss in 2025 on the Bitcoin stack [34] Business Line Data and Key Metrics Changes - In the power segment, revenue was $23.2 million, down from $56.6 million in 2024, while cost of revenue declined to $20.5 million from $21.5 million [35] - Digital infrastructure revenue was $9.6 million compared to $17.5 million last year, with cost of revenue declining to $8.9 million from $15.6 million [36] - Compute revenue more than doubled to $202.3 million from $80.7 million, with cost of revenue increasing to $78.4 million from $45 million, driven by infrastructure upgrades and a full year of steady state operations of Highrise AI [37] Market Data and Key Metrics Changes - The company is focusing on converting existing capacity for AI use cases, with 300 megawatts of power generation sold to TransAlta and 700 megawatts of compute supporting American Bitcoin [46] - The demand environment for high-performance computing (HPC) has evolved positively, with record high utilization on the Highrise cloud and increasing applications and use cases [68] Company Strategy and Development Direction - The company aims to build a durable cash flow and capital-efficient structure, focusing on power control and scalable campuses [3] - The strategic evolution includes a phased approach: Phase 1 focuses on securing deals and monetizing power capabilities, Phase 2 on value engineering to drive costs down, and Phase 3 on integrating AI and robotics into infrastructure development [30][31] - The company emphasizes building infrastructure with AI, leveraging technology to optimize design and construction processes [31] Management's Comments on Operating Environment and Future Outlook - Management highlighted the importance of credibility with shareholders and partners, noting that acceleration in business growth is contingent on earned credibility [8] - The focus for 2026 is on execution and delivery, converting the pipeline to contracted revenue and maintaining capital discipline [32] Other Important Information - The company has a clean balance sheet with minimal recourse debt, positioning itself for strategic flexibility and growth [26] - Stock-based compensation increased significantly, reflecting investments in team growth and alignment with long-term value creation [27][28] Q&A Session Summary Question: Will the company define the allocation of its pipeline between Bitcoin mining and HPC? - The company is focusing on AI utilization and development, with Bitcoin as an alternative use case to support development confidence [46][47] Question: Can you provide details behind the $163 million deposit for future sites? - The deposit is allocated towards land options and long lead time equipment for future sites, with a focus on maintaining competitive advantages [48][49] Question: How has the demand environment for HPC evolved recently? - Demand signals have improved, with record utilization on the Highrise cloud and increasing applications in the market [68]

Financial Data and Key Metrics Changes - In Q4 2025, total revenue grew 14% year-over-year to $44.6 million, with a sequential increase of 16% [7][27] - For the full year 2025, total revenue reached $160 million, representing a 4% growth over 2024 [7][30] - Non-GAAP gross margin improved to 40% in Q4 2025, up from 31% in Q4 2024, and for the full year, it was also 40%, compared to 33% in 2024 [31][24] - Non-GAAP operating expenses decreased to $56.2 million in Q4 2025, down 18% year-over-year, and for the full year, they were $229.9 million, down from $289.2 million in 2024 [32][24] - Cash burn improved from $214 million in 2023 to $105 million in 2025, with approximately $280 million in cash and investments at year-end [25][34] Business Line Data and Key Metrics Changes - Consumable revenue in Q4 2025 increased 15% year-over-year to $21.6 million, driven by an increase in the installed base and consistent system utilization [27][28] - Instrument revenue rose 13% in Q4 to $17.3 million, primarily due to increased shipments of Vega systems [28] - For the full year 2025, consumables revenue increased 16% to $82 million, while instrument revenue decreased 18% to $53.8 million [30] Market Data and Key Metrics Changes - Revenue from the Americas increased 3% to $20.7 million in Q4 2025, while Asia Pacific revenue rose 4% to $9.3 million, and EMEA revenue surged 45% to $14.6 million [29][10] - EMEA's strong growth was attributed to increased Vega instrument shipments and higher Revio consumables as clinical customers transitioned from pilot testing to broader adoption [11][29] Company Strategy and Development Direction - The company aims to enhance the economics of HiFi sequencing through the launch of SparkNex and multi-use smart cells, targeting increased market penetration [37] - Focus areas include accelerating clinical adoption in rare disease, oncology, and carrier screening, as well as enabling population-scale sequencing studies [37] - The company plans to leverage AI to unlock biological insights from multi-omic HiFi data [37] Management's Comments on Operating Environment and Future Outlook - Management anticipates continued growth in clinical markets, particularly in rare disease and whole genome sequencing, despite a challenging academic funding environment [11][54] - The outlook for 2026 projects revenue between $165 million and $180 million, representing approximately 8% growth at the midpoint [34] - Management expects non-GAAP gross margin to improve by 100-400 basis points in 2026, driven by a higher consumables mix and the introduction of SparkNex [35] Other Important Information - The company sold its short-read sequencing assets for net proceeds of approximately $48 million, strengthening its balance sheet and extending its cash runway [26] - The company is committed to supporting existing customers during the transition period following the divestment of short-read assets [26] Q&A Session Summary Question: What should we expect for Revio pull-through and consumables growth? - Management expects SparkNex to lower sample costs, likely increasing utilization and expanding market share, while maintaining pull-through in the range of $225K-$250K [41][43] Question: What is the outlook for clinical growth outside the U.S.? - Management sees strong growth in clinical markets, particularly in EMEA, with significant movement from pilot phases to production [53] Question: Where are the biggest opportunities for OpEx reduction? - Management plans to focus on managing G&A expenses and R&D while continuing to reduce production costs through insourcing [66][68] Question: What impact will the short-read divestment have on costs? - Management indicated that while there won't be substantial additional costs taken out immediately, the divestment will provide a tailwind to gross margin over time [72] Question: How does long-read sequencing compare to standard care in terms of cost? - Long-read sequencing is expected to provide better diagnostic yield, faster turnaround times, and lower overall costs by consolidating multiple tests into one [74]

Financial Data and Key Metrics Changes - In Q4 2025, total revenue grew 14% year-over-year to $44.6 million, with a sequential increase of 16% [7][26] - For the full year 2025, total revenue reached $160 million, representing a 4% growth over 2024 [7][30] - Non-GAAP gross margin improved to 40% in Q4 2025, up from 31% in Q4 2024, and also increased from 33% in 2024 to 40% in 2025 [31][23] - Non-GAAP operating expenses decreased from $355 million in 2023 to $230 million in 2025, a 35% reduction [23][32] - Cash burn improved from $214 million in 2023 to $105 million in 2025, representing a 51% improvement [24] Business Line Data and Key Metrics Changes - Consumable revenue in Q4 2025 increased 15% year-over-year to $21.6 million, driven by an increase in the installed base and consistent system utilization [26][30] - Instrument revenue increased 13% in Q4 2025 to $17.3 million, primarily due to an increase in Vega systems [27] - For the full year 2025, consumables revenue grew 16% to $82 million, while instrument revenue decreased 18% to $53.8 million [30] Market Data and Key Metrics Changes - In Q4 2025, Americas revenue increased 3% to $20.7 million, Asia Pacific revenue increased 4% to $9.3 million, and EMEA revenue surged 45% to $14.6 million [10][29] - EMEA's strong growth was attributed to increased Vega instrument shipments and higher Revio consumables as clinical customers shifted to broader clinical adoption [11][29] Company Strategy and Development Direction - The company aims to improve the economics of HiFi sequencing through the launch of SparkNex and multi-use smart cells [38] - Focus on accelerating clinical adoption in rare disease, oncology, and carrier screening, while enabling population-scale sequencing studies [38] - The strategy includes leveraging AI to unlock biological insights and driving innovation in sequencing technology [38] Management's Comments on Operating Environment and Future Outlook - Management expects 2026 revenue to be in the range of $165 million to $180 million, representing approximately 8% growth at the midpoint [11][34] - The company anticipates continued pressure from the academic funding environment, particularly in the Americas, impacting capital spending [34][35] - Management is optimistic about the growth in clinical markets, especially in EMEA, despite the challenges in the academic sector [53] Other Important Information - The company sold its short-read sequencing assets for net proceeds of approximately $48 million, strengthening its balance sheet [25] - The introduction of SparkNex is expected to enhance gross margins and improve the overall financial profile [21][23] Q&A Session Summary Question: What should we expect OUS to do this year from a clinical growth perspective? - Management noted strong growth in clinical markets, particularly in rare disease and whole genome sequencing, especially in EMEA, with customers moving from pilot phases to production [53] Question: Where's the biggest opportunity to reduce OpEx spending this year? - Management indicated a focus on managing G&A expenses and R&D while maintaining critical programs, with a goal to reduce non-headcount-related spending [66] Question: Did you see any budget flush, particularly from Europe in full Q25? - Management did not observe significant budget flush but noted some opportunistic purchasing [51][52]

Financial Data and Key Metrics Changes - In Q4 2025, total revenue grew 14% year-over-year to $44.6 million, with a sequential increase of 16% [5][25] - For the full year 2025, total revenue reached $160 million, representing a 4% growth over 2024 [5][29] - Non-GAAP gross margin improved to 40% in Q4 2025, up from 31% in Q4 2024, and for the full year, it was also 40%, compared to 33% in 2024 [30][22] - Non-GAAP operating expenses decreased to $56.2 million in Q4 2025, down 18% year-over-year, and for the full year, they were $229.9 million, down from $289.2 million in 2024 [31][22] Business Line Data and Key Metrics Changes - Consumable revenue in Q4 2025 increased 15% year-over-year to $21.6 million, driven by a growing installed base and consistent system utilization [25][6] - Instrument revenue rose 13% in Q4 2025 to $17.3 million, primarily due to increased shipments of Vega systems [26] - For the full year 2025, consumables revenue increased 16% to $82 million, while instrument revenue decreased 18% to $53.8 million [29] Market Data and Key Metrics Changes - Revenue from the Americas increased 3% to $20.7 million in Q4 2025, while Asia Pacific revenue grew 4% to $9.3 million, and EMEA revenue surged 45% to $14.6 million [27][28] - The strong growth in EMEA was attributed to increased clinical adoption and higher shipments of Vega instruments [28] Company Strategy and Development Direction - The company aims to improve the economics of HiFi sequencing through the launch of SparkNex and multi-use smart cells, targeting increased market penetration [37] - Focus areas include accelerating clinical adoption in rare disease, oncology, and carrier screening, as well as enabling population-scale sequencing studies [37] - The company plans to leverage AI to unlock unique biological insights from multi-omic HiFi data [37] Management's Comments on Operating Environment and Future Outlook - Management anticipates continued growth in clinical markets, particularly in rare disease and whole genome sequencing, despite a challenging academic funding environment [9][52] - The outlook for 2026 projects revenue between $165 million and $180 million, representing approximately 8% growth at the midpoint [33] - Management expects non-GAAP gross margin to improve by 100-400 basis points in 2026, driven by a higher consumables mix and the introduction of SparkNex [34] Other Important Information - The company ended 2025 with approximately $280 million in cash and investments, down from $389.9 million at the end of 2024 [23][33] - The recent sale of short-read sequencing assets for approximately $48 million is expected to strengthen the balance sheet and extend the cash runway [24] Q&A Session Summary Question: What should we expect OUS to do this year from a clinical growth perspective? - Management noted strong growth in clinical markets, particularly in EMEA, with many customers moving from pilot testing to broader clinical adoption [52] Question: What is the biggest opportunity to reduce OpEx spending this year? - Management indicated a focus on managing G&A expenses and R&D while maintaining funding for critical programs [66] Question: Did you see any budget flush, particularly from Europe in full Q25? - Management did not observe significant budget flush but noted some opportunistic purchasing [51]

Q4 & Full Year 2025 Earnings Presentation February 12, 2026 1 Safe harbor and non-GAAP disclosures Statement regarding use of non‐GAAP financial measures PacBio reports non‐GAAP results for basic net income and loss per share, net income, net loss, gross margins, gross profit and operating expenses in addition to, and not as a substitute for, or because it believes that such information is superior to, financial measures calculated in accordance with GAAP. PacBio believes that non-GAAP financial information ...

Financial Data and Key Metrics Changes - The IT services revenue for Q3 FY26 was $2.64 billion, reflecting a sequential growth of 1.4% in constant currency and 1.2% in reported currency [5][11] - Year-on-year revenue growth was flat at 0.2% in reported terms but declined by 1.2% in constant currency terms [11] - Operating margin improved to 17.6%, an increase of 40 basis points quarter-on-quarter and 10 basis points year-on-year [11][12] - Adjusted net income for the quarter was INR 33.6 billion, with adjusted EPS at INR 3.21, marking a 3.5% increase quarter-on-quarter and flat year-on-year [12] Business Line Data and Key Metrics Changes - Americas 1 grew 1.8% sequentially and 2.8% year-on-year, while Americas 2 saw a decline of 0.8% sequentially and 5.2% year-on-year [12] - Europe experienced a sequential growth of 3.3% but a year-on-year decline of 4.6% [12] - APMEA grew 1.7% sequentially and 6.6% year-on-year, with BFSI growing 2.6% sequentially and 0.4% year-on-year [12][13] - The consumer sector grew 0.7% sequentially but declined 5.7% year-on-year [12] Market Data and Key Metrics Changes - The Americas 1 market showed strong performance in healthcare, consumer, and LATAM, while Europe saw growth driven by a ramp-up of a previously announced mega deal [6][12] - APMEA's growth was led by India, the Middle East, and Southeast Asia, with BFSI showing strong traction [7] Company Strategy and Development Direction - The company is positioning itself for an AI-first world, focusing on AI-led transformation, cost optimization, and vendor consolidation [4][5] - Wipro Intelligence is a unified approach to delivering AI-powered transformation across industries, anchored on industry platforms, delivery platforms, and an innovation network [7][8] - The acquisition of Harman DTS is expected to enhance engineering capabilities and accelerate AI-driven product innovation [10] Management's Comments on Operating Environment and Future Outlook - Management noted that organizations are reshaping priorities due to AI's influence on business models and operations [4] - The guidance for Q4 projects IT services revenue growth of 0%-2% in constant currency, impacted by fewer working days and delayed ramp-ups [10][14] - Management expressed confidence in the deal pipeline, particularly in energy and manufacturing sectors, despite current macroeconomic uncertainties [20][23] Other Important Information - The board declared an interim dividend of INR 6 per share, with total cash distributed to shareholders exceeding $1.3 billion for the financial year [15] - The company has a gross cash position of $6.5 billion, indicating strong liquidity [14] Q&A Session Summary Question: Concerns about revenue loss in energy manufacturing resources - Management acknowledged a $24 million revenue loss in the EMR vertical, attributing it to macroeconomic uncertainties and supply chain issues, but noted a strong deal pipeline [17][20] Question: Delays in ramp-ups impacting growth - Management indicated that some deals would take a few quarters to ramp up, with confidence in future growth as these deals convert [18][19] Question: Outlook for the consumer vertical - Management highlighted tariff impacts and a large SAP program on hold, but noted that some earlier wins are ramping up [28][29] Question: Impact of Harman DTS acquisition on growth - Management stated that the acquisition would enhance capabilities in tech and communications sectors, improving win rates [41][42] Question: Future of buybacks and excess cash - Management confirmed that buybacks remain an option for returning cash to shareholders, contingent on market conditions and statutory considerations [74][75]

Financial Data and Key Metrics Changes - The IT services revenue for Q3 FY26 grew 1.4% sequentially in constant currency terms, and 1.2% in reported currency terms [10] - Year-on-year revenue growth was 0.2% in reported terms, while it declined 1.2% in constant currency terms [10] - Operating margin for the quarter was 17.6%, an expansion of 40 basis points over the adjusted operating margin for Q2, and a 10 basis points improvement year-on-year [10][11] - Adjusted net income for the quarter was INR 33.6 billion, with adjusted EPS at INR 3.21, reflecting a 3.5% quarter-on-quarter increase and flat year-on-year [11] Business Line Data and Key Metrics Changes - Americas 1 grew 1.8% sequentially and 2.8% year-on-year, while Americas 2 declined 0.8% sequentially and 5.2% year-on-year [11] - Europe grew 3.3% sequentially but declined 4.6% year-on-year [11] - APMEA grew 1.7% sequentially and 6.6% year-on-year, with BFSI growing 2.6% sequentially and 0.4% year-on-year [11][12] - Health sector grew 4.2% sequentially and 1% year-on-year, while Consumer grew 0.7% sequentially but declined 5.7% year-on-year [11][12] - Communications grew 4.2% sequentially and 3.5% year-on-year, while EMR declined 4.9% sequentially and 5.8% year-on-year [12] Market Data and Key Metrics Changes - The Americas 1 market showed strong performance in healthcare, consumer, and LATAM, while Europe saw growth driven by a ramp-up of a previously announced mega deal [5][6] - APMEA's growth was led by India, the Middle East, and Southeast Asia, with BFSI showing strong traction [6] Company Strategy and Development Direction - The company is positioning itself for an AI-first world, focusing on AI-led transformation, cost optimization, and vendor consolidation [4][5] - Wipro Intelligence is a unified approach to delivering AI-powered transformation across industries, anchored on industry platforms, delivery platforms, and an innovation network [6][7] - The acquisition of Harman DTS is expected to enhance engineering capabilities and accelerate AI-driven product innovation [9] Management's Comments on Operating Environment and Future Outlook - Management noted that organizations are reshaping priorities as AI influences their operations, with a clear shift towards AI-led transformation [4] - The guidance for Q4 projects IT services revenue growth of 0%-2% in constant currency, impacted by fewer working days and delayed ramp-ups in large deals [9][14] Other Important Information - The board declared an interim dividend of INR 6 per share, with total cash distributed to shareholders exceeding $1.3 billion for the financial year [15] - The company has a gross cash position of $6.5 billion, with net other income growing 15% sequentially [14] Q&A Session Summary Question: Concerns about revenue loss in energy manufacturing resources and deal pipeline outlook - Management acknowledged the revenue loss in EMR and noted that the pipeline remains strong, with good momentum in energy sectors in both Americas and Europe [17][20] Question: Delays in ramp-ups impacting growth for next quarter - Management indicated that some deals will take time to ramp up, and while Q4 may not realize full impacts, they are confident in future growth [18][19] Question: Outlook for consumer vertical and tariff impacts - Management confirmed that tariff uncertainties have impacted the consumer sector, but some earlier wins are ramping up, which should support future growth [29][30] Question: Insights on tech and healthcare verticals - Management noted consistent performance in healthcare, driven by seasonal factors, and highlighted growth in tech due to the Harman acquisition [32][33] Question: Guidance on margins and potential buyback options - Management stated that while margins are expected to remain in the 17%-17.5% band, they will need to invest for growth, and buyback remains an option for returning cash to shareholders [48][51][75]